25 jul: Symantec 1st-Quarter Net Down 9.9% on Costs; CEO Enrique Salem St..
25 jul: Turkey Business Confidence Falls in July
25-07-2012 14:05:00

Bristol-Myers Profit Falls 28%

Relateret indhold

Bristol-Myers Squibb Co.'s (BMY) second-quarter profit declined 28%, as sales were eroded by recent patent expirations for top-selling drugs including the anticlotting pill Plavix.

The New York drug maker also lowered its forecast of full-year 2012 earnings.

Bristol-Myers plans to get through the patent losses for Plavix and other drugs by boosting sales of newer drugs. The company hopes to bolster its product lineup with its recent agreement to purchase diabetes-drug maker Amylin Pharmaceuticals Inc. (AMLN) for $5.3 billion.

In May, Bristol-Myers lost U.S. patent protection for Plavix, which is used to stave off recurrent heart attacks and strokes. This exposed the brand to lower-priced competition from generic versions, and Bristol's second-quarter Plavix sales tumbled 60% to $741 million. Bristol-Myers co-markets the drug with Sanofi (SNY).

Another blow was the March loss of patent protection for blood-pressure medications Avapro and Avalide, which pushed combined sales of those drugs down 53% to $117 million.

Bristol and other drug makers are in the midst of a wave of patent expirations for blockbuster drugs that have pressured sales. Bristol has had some success bringing new drugs to market to help offset the patent losses, but it also has experienced some research setbacks.

For the second quarter, Bristol's profit fell to $645 million, or 38 cents a share, from $902 million, or 52 cents a share, a year earlier. Excluding certain costs such as asset impairments, earnings were 48 cents a share, matching the mean estimate of analysts surveyed by Thomson Reuters.

Overall sales declined 18% to $4.44 billion, just ahead of the Thomson mean estimate.

U.S. sales dropped 27% to $2.6 billion, while non-U.S. sales fell 1% to $1.9 billion.

Although sales for Plavix and the blood-pressure medications declined substantially, sales for other top products increased, ranging from a 1% gain for antipsychotic Abilify to a 71% jump for skin-cancer treatment Yervoy.

Bristol-Myers continues to try to bring more drugs to market. One of the most closely watched is Eliquis, an anticlotting drug co-developed with Pfizer Inc. (PFE). The U.S. Food and Drug Administration declined to approve it in June, asking for more information about clinical data. Analysts believe the drug could be a multibillion-dollar seller.

Bristol also is developing new drugs for cancer and hepatitis C that have shown promise in studies.

The company, however, recently disclosed negative clinical results for experimental liver-cancer drug brivanib. And the FDA has declined to approve the diabetes drug dapagliflozin, developed in partnership with AstraZeneca PLC (AZN).

Bristol said Wednesday an advisory committee of the European Union issued a positive opinion on the company's proposed subcutaneous formulation of anti-inflammatory drug Orencia. A European Commission decision is pending.

The company lowered its forecast of 2012 earnings to a range of $1.78 to $1.88 a share from a prior range of $1.90 to $2 a share. However, Bristol didn't change its forecast of adjusted earnings, which exclude certain items, of $1.90 to $2 a share. Bristol said the unchanged adjusted earnings forecast factors in the expected three-cents-a-share negative impact related to the planned Amylin acquisition.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 25, 2012 08:05 ET (12:05 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
27 jul
AZN
Nu har Præsident Obama fået nok af amerikanske virksomheder som laver en såkaldt ”inversion”, hvor m..
5
27 jul
AZN
Og så ved delfinen ikke om han bliver brandbeskattet ved udbetalingen, det er set før ;)   Så Delfin..
4
27 jul
AZN
Vel gør du ej. Du betaler 15,3% i palskat, og når pengene udbetales når du pensioneres så trækkes di..
3
27 jul
AZN
Jeg synes det er upatriotisk af Coca cola at de sælger så meget i Danmark, men sender pengene til Ir..
3
27 jul
AZN
Jeg er også upatriotisk, når jeg indbetaler på min ratepension udelukkende for at betale mindre skat..
2
27 jul
AZN
Det kræver at han skal tage et opgør med hele corporate america. Det tør han ikke, det kan han ikke...
2

Fondsbørsmeddelelser

Vind: Nordex henter ordre på 50 MW i Uruguay

29-07-2014 10:45:49
Den tyske vindmølleproducent Nordex, der konkurrerer med blandt andre danske Vestas, har hentet en ordre på samlet 50 megawatt (MW) i Uruguay.Det fremgår af en ..

Aktier/tendens: Positiv start i vente efter amerikansk rebound

29-07-2014 08:30:56
Efter et par dage i træk med fremgang faldt de danske aktier atter tilbage mandag, hvor der aldrig for alvor var optimisme at spore, efter at markedet herhjemme..

KORR: Nordea kan stå over for dilemma i Rusland - medie

28-07-2014 15:40:39
(Rettet så det fremgår, at der er tale om potentiel situation + tilføjet afsnit i bunden + rettet rubrik)Skærpede sanktioner mod Rusland er på vej, men de vil i..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Ukendt kunde hæver knap 40 mia. kr. i skotsk selskab
2
Danske Bank: Nye kursmål og anbefalinger efter regnskab - NY3
3
Boligejerne høvler af gælden som aldrig før
4
Vestas: Tysk vindmarked opjusteres efter kraftigt halvårsvækst
5
Aktier/tendens: Positiv start i vente efter amerikansk rebound

Relaterede aktiekurser

Astrazeneca PLC ORD SHS .. 4.344,60 -0,4% Fald i aktiekurs
Sanofi 77,24 1,2% Stigning i aktiekurs
Pfizer Inc 30,10 0,0% Aktiekurs uændret
Astrazeneca PLC 73,89 0,0% Aktiekurs uændret
Sanofi 51,18 0,0% Aktiekurs uændret
Bristol-Myers Squibb Co 49,80 0,0% Aktiekurs uændret
AstraZeneca PLC 503,50 -0,6% Fald i aktiekurs
Pfizer Inc 206,50 0,7% Stigning i aktiekurs
Pfizer 27,25 0,0% Aktiekurs uændret
Pfizer Incorporated COM .. 29,97 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
29. juli 2014 14:46:09
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140723.1 - EUROWEB4 - 2014-07-29 14:46:09 - 2014-07-29 14:46:09 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x